Slide 1 The Problem with Thresholds in Evaluating the Cost-Effectiveness of Global Health Programs Elliot Marseille, DrPH, MPP – Health Strategies International.

Slides:



Advertisements
Similar presentations
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlikeLicense. Your use of this material constitutes acceptance of that license.
Advertisements

Choosing services Integrating Concerns for Cost-Effectiveness, Financial Protection, and the Worse Off Ole F. Norheim Professor in Medical Ethics and Philosophy.
Institute for Public Health, Medical Decision Making and Health Technology Assessment 1 Results of the PanEuropean Hepatitis C Project 3 rd Paris Hepatitis.
MANAGERIAL ACCOUNTING
T9.1 Chapter Outline Chapter 9 Net Present Value and Other Investment Criteria Chapter Organization 9.1Net Present Value 9.2The Payback Rule 9.3The Average.
Net Present Value and Other Investment Criteria
0 Net Present Value and Other Investment Criteria.
Copyright © 2012 Pearson Prentice Hall. All rights reserved. Chapter 10 Capital Budgeting Techniques.
Chapter 9 INVESTMENT CRITERIA Pr. Zoubida SAMLAL GF 200.
1 Are you sure your improvements are cost-effective? Edward Broughton, PhD, MPH, PT University Research Co. April 11, 2014
Making Decisions in Health Care: Cost-effectiveness and the Value of Evidence Karl Claxton Centre for Health Economics, Department of Economics and Related.
We show that MP can be used to allocate resources to treatments within and between patient populations, using a policy-relevant example. The outcome is.
Transforming the cost-effectiveness threshold into a ‘value threshold’ Initial findings from a simulation model Mike Paulden and Christopher McCabe.
Ch 6 Project Analysis Under Certainty
CAPITAL BUDGETING AND CAPITAL BUDGETING TECHNIQUES FOR ENTERPRISE Chapter 5.
Balancing efficiency and equity in formal economic evaluation of health care. Erik Nord, Senior Researcher, Norwegian Institute of Public Health, Professor.
Alternative antiretroviral monitoring strategies for HIV-infected patients in resource-limited settings: Opportunities to save more lives? R Scott Braithwaite,
A METHODOLOGY FOR MEASURING THE COST- UTILITY OF EARLY CHILDHOOD DEVELOPMENTAL INTERVENTIONS Quality of improved life opportunities (QILO)
Should Decision-Makers Embrace “Non- Constant” Discounting? Mike Paulden Samprita Chakraborty Valentina Galvani Christopher McCabe.
Economic evaluation considers assessment of intervention effects in economic terms, which is often of greatest interest to fund allocators Intervention.
Dangerous Omissions – the Cost of Ignoring Decision Uncertainty Mark Sculpher Susan Griffin Karl Claxton Steve Palmer Centre for Health Economics, University.
© 2003 The McGraw-Hill Companies, Inc. All rights reserved. Net Present Value and Other Investment Criteria Chapter Nine.
The Use of Decision Analysis in Program Evaluation Farrokh Alemi, Ph.D.
Cost-effectiveness Analysis: A practical primer Eran Bendavid.
The Panel on Cost-Effectiveness in Health and Medicine Marthe Gold City University of London 30 October, 2003.
1 Cost-Effectiveness Analysis (CEA) Scott Matthews Courses: and Lecture /3/2003.
AGEC 608 Lecture 17, p. 1 AGEC 608: Lecture 17 Objective: Review the main aspects of cost- effectiveness analysis (CEA) and cost-utility analysis (CUA).
Health Economics & Policy 3 rd Edition James W. Henderson Chapter 4 Economic Evaluation in Health Care.
Economic Evaluations, Briefly… CHSC 433 Module 6/Chapter 13 UIC School of Public Health L. Michele Issel, PhD, R N.
3rd Baltic Conference on Medicines Economic Evaluation, Reimbursement and Rational Use of Pharmaceuticals Pricing and Reimbursement of Pharmaceuticals.
FOOD ENGINEERING DESIGN AND ECONOMICS
1 Cost-effectiveness of improving medical services in low-resource settings Edward Broughton, PhD, MPH, PT University Research Co. May 21, 2014
Cost-Effectiveness Problem l You have a $1.5 billion budget to spend on any combination of these programs:
CENTRE FOR HEALTH ECONOMICS AND DEVELOPEMNT ESTIMATING ECONOMIC AND FISCAL IMPACT OF HEALTH AND NON HEALTH EXPENDITURE FROM THE NATIONAL HEALTH BILL Kenneth.
1 Econoqualimetrics Edward Broughton, PhD., MPH Senior Economic Analyst, USAID Health Care Improvement Project, EnCompass,
Taxes on the Longevity Dividend: Can we Reduce Them? Lessons from the Theoretical Foundations of Medical Cost-Effectiveness Analysis David Meltzer MD,
BIOE 301 Lecture Thirteen. HIV/AIDS Vaccine Update.
EVIDENCE BASED MEDICINE Health economics Ross Lawrenson.
Knowing what you get for what you pay An introduction to cost effectiveness FETP India.
Lecture Thirteen Biomedical Engineering for Global Health.
Why Use MONAHRQ for Health Care Reporting? May 2014 Note: This is one of seven slide sets outlining MONAHRQ and its value, available at
Cost-Effectiveness Thresholds Professor of Health Economics
Decision-making and goal-setting skills are needed to help you make health-enhancing choices; to choose behaviors that promote health and reduce the risk.
25 July 2012 James G. Kahn, MD, MPH UCSF. Goal of analysis  Estimate the cost, health effects, and cost-effectiveness of a diarrhea, malaria and HIV.
Net Present Value and Other Investment Rules. Percent of CFOs who say they use the following rules to evaluate projects 2.
انواع ارزيابي های اقتصادي سيدرضا مجدزاده مرکز تحقيقات بهره برداری از دانش سلامت و دانشکده بهداشت دانشگاه علوم پزشکي و خدمات بهداشتي درماني تهران.
Economic evaluation of health programmes Department of Epidemiology, Biostatistics and Occupational Health Class no. 23: Nov 17, 2008.
Breastfeeding : Challenges and Opportunities Arun Gupta MD FIAP 2nd National Conference on Breastfeeding and Complementary Feeding (Infant and young Child.
Net Present Value and Other Investment Criteria By : Else Fernanda, SE.Ak., M.Sc. ICFI.
Net Present Value and Other Investment Rules
Flagship Program on Health Sector Reform and Sustainable Financing.
Anne Matthews, Health & Society, School of Nursing and Human Sciences, DCU The paradox of ‘low quality evidence; strong recommendation’: An analysis of.
Questions from the National President concerning: NCMA CHAPTER REBATE POLICY UPDATE Board of Directors Meeting 24 January 2009 Las Vegas, NV.
Cost-Effectiveness and Outcomes Research Setting value to what we do.
BIOE 301 Lecture Sixteen. Review of Lectures What is the goal of cancer screening? Successful cancer screening examples? Can screening hurt more.
© University of South Wales Royal College of Speech and Language Therapists Outcomes Conference and Hub Launch Belfast, May 1, 2014 Running a tight ship:
Medicines adherence Implementing NICE guidance 2009 NICE clinical guideline 76.
1 Edward Broughton, PhD., MPH Director of Research and Evaluation, USAID Health Care Improvement Project, University Research Co., LLC
FUNDAMENTALS OF PUBLIC HEALTH Joseph S Duren Lopez Community & Public Health - HCA415 Instructor: Adriane Niare November 10, 2015.
Economics for Commissioning Angela Bate. IHS, Newcastle University UK.
HN BUSINESS HND GRADED UNIT 3
Burden of Disease and Health Economics: Friends or Foes?
HEALTH ECONOMICS BASICS
Breastfeeding : Challenges and Opportunities
Economic Evaluation of Health Interventions Basic Concepts
Capital Budgeting Techniques FHU3213
Acceptability curve. Acceptability curve. In our PSA, the within-trial analysis of the mass media campaign in Burkina Faso had a less than 1% probability.
Capital-Budgeting Techniques.
BIOE 301 Lecture Sixteen.
Rita Faria, MSc Centre for Health Economics University of York, UK
Presentation transcript:

Slide 1 The Problem with Thresholds in Evaluating the Cost-Effectiveness of Global Health Programs Elliot Marseille, DrPH, MPP – Health Strategies International James G. Kahn, MD, MPH – UCSF Webinar on Cost-Effectiveness Thresholds Center for Global Development Thursday, June 4, 2015

Presentation based on: Marseille E, Larson B, Kazi DS, Kahn JG, Rosen S. Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ. 2015;93(2):

The Basics: Obvious but important Cost-effectiveness is a relative concept. If analysts or decision makers are unwilling or unable to say that an intervention is, or is not, CE compared to another option, CEAs cannot help decide how $$ should be spent. Thus – some standard method of determining CE is indispensable Thus – some standard method of determining CE is indispensable CE is not the only criterion for guiding resource allocation...

The problem Many CEAs in global public health define cost-effectiveness by a standard which is theoretically hard to justify, and leads to severe practical problems in the application of CEA as a guide to resource allocation.

The WHO CE Threshold Promoted by WHO’s Choosing Interventions that are Cost–Effective (WHO-CHOICE) project. Definition: an intervention that, per DALY avoided, costs less than: 3 x the annual GDP per capita is CE, 1 x annual GDP per capita is considered highly CE.

This standard has become ubiquitous “According to World Health Organization guidelines these strategies are all highly cost-effective because they cost less than [the country ’ s] per-capita GDP” (Alistair, 2011) “(The intervention) for adolescents is slightly less than one GDP/ per-capita/life year gained and therefore highly cost-effective, while for adults it is less than two GDP/per-capita/life year gained and therefore potentially cost-effective. ( Binagwaho, 2010) “We compared the estimates to a benchmark for cost- effectiveness of one times the gross domestic product per-capita (GDP/capita) per DALY averted, per QALY gained, or per life- year saved…” ( Gomez 2013)

Slide 7 What’s the problem with the WHO threshold approach?   Important comparisons among locally relevant options are ignored   Threshold is too easily attained.   Weak theoretical basis   Affordability not addressed Result: CEA far less helpful as a guide to policy than it could be. When used, potential for error.

Important comparisons are obscured Interventions are lumped together as “CE” or “very CE” regardless of their incremental CE ratio (ICER) Means that options with huge differences in CE will be treated the same. Relevant question: “Is Option ‘A’ a better use of limited budget than Option ‘B’? Tends to suggest that finer distinctions cannot be support by existing data and methods; subtly undermines credibility of CEA enterprise.

WHO threshold is easily attained if effective, cost-effective: an example In SSA, annual child risk of death from diarrhea ~1% Death = 28 DALYs; ignore morbidity. Annual DALY burden = 28 * 0.01 = ~0.3 per HH w/1 child. Clean water -- I$37 per year Well-powered trials detect risk drop of 20%, or 10% at best At 20%, intervention averts 0.06 (0.2 × 0.3) DALYs, ICER = I$37 / 0.06 = I$614 per DALY averted. At 10%, I$1228 PDA Both ICERs << I$5211, WHO CHOICE threshold for “cost- effective” in Kenya. Even if effectiveness at 5%, still CE. Thus, effective implies cost-effective. Better to de-link.

Weak theoretical basis Justification for per-capita GDP metric is not stated by WHO CHOICE or the Commission on Macroeconomics and Health. Tacit assumption that people are WTP up to the threshold. Assumes that WTP for healthcare increases linearly with national income; whereas reason to believe that health care is a ‘superior good’. Was the WHO threshold chosen in part to ensure that ART for HIV would be considered CE?

Thresholds are unrelated to budgets; fail to address affordability   Trade-offs and opportunity costs are at the heart of CEA   These only have meaning in the context of finite budgets.   Imagine a drug that adds 1 year of life to everyone and costs 1x pc-GDP.   “Highly CE”   Would require HC budget = entire GDP Like a teenager at a shopping mall, it’s possible to go broke saving money.

The temptation is great Very easy to use. Has imprimatur of premier standards-setting body in global health (WHO). Everyone else uses it. For journals, having a globally accepted standard reassures editors and reviewers that the methods and results meet international norms. Encourages authors and reviewers to choose convenience over a more nuanced, and setting- relevant examination of a complex issue.

Possible solutions Increase the link to local context, revealed or stated WTP and budgets Benchmark interventions Benchmark interventions League tables League tables

Benchmark interventions Uses ICER of intervention already widely adopted Uses ICER of intervention already widely adopted Thus (may) reveal actual WTP. Thus (may) reveal actual WTP. More closely linked to local context but otherwise several drawbacks. More closely linked to local context but otherwise several drawbacks. Does it really represent WTP? May be outlier. Does it really represent WTP? May be outlier. Needs updating Needs updating Shares other shortcomings of threshold approach b/c it is a threshold approach. Shares other shortcomings of threshold approach b/c it is a threshold approach.

League tables Given a budget, health benefit maximized if the most CE options are selected; moving down the list (‘league table’) to successively less CE options until budget is exhausted.

League Tables: Pros and Cons ‘Pros’ Budget and affordability are front and center Budget and affordability are front and center No one cut-off; rather reflects relative CE of many interventions No one cut-off; rather reflects relative CE of many interventions Least CE option that can be funded more likely to represent societal WTP than is a threshold or benchmark Least CE option that can be funded more likely to represent societal WTP than is a threshold or benchmark

League Tables: ‘Cons’ and solutions ICERs in local context may be unavailable for any relevant options ICERs in local context may be unavailable for any relevant options ‘Bare’ league table that just gives ICERs will not provide needed context for policy makers. ‘Bare’ league table that just gives ICERs will not provide needed context for policy makers. Solutions / mitigating techniques: 1. ‘Borrow’ CE information from similar settings; program contexts; 2. Develop “Extended League Table” in which ICERs are accompanied by information that helps situate each entry in relation to the policy question at hand.

Conclusion The current WHO threshold approach for determining CE needs to be replaced by methods which account for budgets, permit multiple comparisons, and more closely approximate WTP. The current WHO threshold approach for determining CE needs to be replaced by methods which account for budgets, permit multiple comparisons, and more closely approximate WTP. An ‘extended league table’ approach may be promising. An ‘extended league table’ approach may be promising. The BMGF and NICE (UK) are concerned with this issue. Meeting in London later this month to assess and chart the way forward.